PDF(Pubmed)
Abstract：
Hepatocellular carcinoma (HCC) usually occurs in settings of cirrhosis and chronic hepatitis B or C virus (HBV and HCV, respectively) infection; it is extremely rare in patients <40 years of age since viral- or alcohol-induced chronic hepatitis develops over a prolonged period. Juvenile HCC is mostly associated with persistent HBV infection; cases unrelated to HBV or HCV infection (non-B, non-C juvenile HCC) are sporadic and treated in the same way as classical HCC. A woman in her late 30s was diagnosed with HCC in a healthy liver; her imaging findings were typical of HCC with bone metastasis. She was administered a combination of tyrosine kinase inhibitors, immune checkpoint inhibitors, and vascular endothelial growth factor inhibitors. Throughout chemotherapy, the liver reserve was Grade A on the Child-Pugh classification and tumor markers remained under control without marked elevation. Our patient is the first reported long-term survivor of unresectable non-B, non-C juvenile HCC following chemotherapeutic treatment.
摘要：
肝细胞癌（HCC）通常发生在肝硬化和慢性乙型肝炎或丙型肝炎病毒（HBV和HCV，分别）感染；在40岁以下的患者中极为罕见，因为病毒或酒精引起的慢性肝炎会长期发展。青少年肝癌主要与持续HBV感染有关;与HBV或HCV感染无关的病例（非B，非C青少年HCC）是散发性的，治疗方式与经典HCC相同。一名30多岁的女性在健康的肝脏中被诊断出患有HCC；她的影像学发现是典型的HCC骨转移。她接受了酪氨酸激酶抑制剂的联合治疗，免疫检查点抑制剂，血管内皮生长因子抑制剂.在整个化疗过程中，肝脏储备Child-Pugh分级为A级,肿瘤标志物仍处于控制状态,无明显升高.我们的患者是第一个报告的无法切除的非B的长期幸存者，非C青少年肝癌化疗治疗后。
